Biosimilars vs Generics: What Is Actually Different

The words get used interchangeably and they should not be. A generic and a biosimilar are approved on different evidence, for different reasons, and the difference is worth understanding before you buy either.

The short version

A generic is a copy of a small-molecule drug — something built by chemical synthesis, with a defined structure that can be reproduced exactly. Paracetamol is paracetamol regardless of who made it.

A biosimilar is a copy of a biologic — a large, complex protein grown in living cells. Living systems do not produce perfectly identical output batch to batch, not even for the original manufacturer. So a biosimilar is *highly similar* to its reference product, with no clinically meaningful differences, rather than identical.

Why the distinction exists

Compare the scale. Aspirin has 21 atoms. A monoclonal antibody has more than 20,000, folded into a specific three-dimensional shape, with sugar chains attached at particular points. The folding and those sugars affect how the drug behaves.

You cannot synthesise that in a reactor and verify it by chemical analysis alone. It is grown, and the manufacturing process is effectively part of the product's definition.

How each gets approved

For a generic, the manufacturer demonstrates bioequivalence: the same active ingredient, the same strength and route, and blood levels that fall within an accepted range of the original. No new efficacy trials are required, because chemical identity plus equivalent exposure implies equivalent effect.

For a biosimilar, the manufacturer runs a comparability exercise — an extensive analytical characterisation comparing structure and function against the reference product, then pharmacokinetic studies, and usually at least one clinical trial in a sensitive patient population. The evidence package is far larger, which is why biosimilars cost more to develop and discount less steeply.

• Generic: typically 80-85% cheaper than the originator
• Biosimilar: typically 15-40% cheaper

Are biosimilars as good?

The regulatory position, across the EMA, FDA and WHO, is that an approved biosimilar can be used wherever the reference product is used, within its approved indications. Years of real-world use across oncology, rheumatology and diabetes have not produced evidence of meaningful differences in outcome.

Two practical caveats:

• Switching should be a clinical decision, recorded in the notes — not something that happens invisibly at the pharmacy counter. Some countries permit automatic substitution for biosimilars; many do not.
• Immunogenicity — the possibility of the body forming antibodies against the drug — is monitored for biologics generally, originator and biosimilar alike.

What this means when sourcing internationally

Read the label rather than the price. A biologic sold far below the usual biosimilar discount is a reason to ask questions, not a bargain. Legitimate biosimilars carry a distinct brand name alongside the international non-proprietary name, and an identifiable manufacturer with a regulatory approval you can look up.

For anything grown rather than synthesised, storage matters as much as authenticity — see safe storage and shipping and how to check a medicine is genuine.

You can browse our manufacturers to see who makes what we carry.

This article is general information, not medical advice. Treatment decisions belong with a qualified clinician who knows your history. Every medicine mentioned is prescription-only and requires a valid prescription.